	US 11,786,585 B2
	Anti-IGFBP-3R antibodies and methods of treating an IGFBP-3R expressing cancer
Youngman Oh, Glen Allen, VA (US); and Qing Cai, Richmond, VA (US)
Assigned to Virginia Commonwealth University, Richmond, VA (US)
Filed by VIRGINIA COMMONWEALTH UNIVERSITY, Richmond, VA (US)
Filed on Nov. 22, 2021, as Appl. No. 17/532,397.
Application 17/532,397 is a continuation of application No. 16/346,353, granted, now 11,179,451, previously published as PCT/US2017/059244, filed on Oct. 31, 2017.
Claims priority of provisional application 62/502,917, filed on May 8, 2017.
Claims priority of provisional application 62/415,620, filed on Nov. 1, 2016.
Prior Publication US 2022/0152177 A1, May 19, 2022
Int. Cl. A61K 39/395 (2006.01); A61K 39/00 (2006.01); C07K 16/28 (2006.01); A61P 35/00 (2006.01); G01N 33/574 (2006.01); A61P 35/04 (2006.01)

CPC A61K 39/001102 (2018.08) [C07K 16/28 (2013.01); A61K 2039/505 (2013.01); A61P 35/00 (2018.01); A61P 35/04 (2018.01); C07K 2317/73 (2013.01); C07K 2317/75 (2013.01); G01N 33/57492 (2013.01); G01N 2333/71 (2013.01); G01N 2800/52 (2013.01)]

5 Claims

1. An antibody that binds to and activates the insulin-like growth factor-binding protein 3 receptor (IGFBP-3R), wherein the antibody contains the complementarity determining regions (CDRs) SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, and the amino acid sequence ATS.